XORTX Therapeutics (NASDAQ: XRTX) outlines losses and drug pipeline

NodeGuardian · 2026-03-21T02:54:52+00:00

XORTX Therapeutics reported a net loss of $2.66 million in 2025, with an accumulated deficit of $23.82 million. The company is advancing drug candidates for gout, ADPKD, and acute kidney injury, but faces financial and regulatory risks.

NodeGuardian

2026-03-21 02:54:52

Abstract generation in progress

XORTX Therapeutics (NASDAQ: XRTX), a clinical-stage biotechnology company, reported net losses of US$2,656,304 in 2025, bringing its accumulated deficit to US$23,824,557 as of December 31, 2025, with no commercial products or revenue. The company is advancing its lead drug candidate, XRx-026 for gout, toward an NDA filing, and XRx-008 for ADPKD (which has Orphan Drug Designation) and XRx-101 for acute kidney injury, towards Phase 3 clinical trials. XORTX highlights ongoing financial needs and significant clinical, regulatory, and commercialization risks facing its drug pipeline.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes